Cochrane · systematic review · CD010509
Aclidinium bromide for stable chronic obstructive pulmonary disease
Ni, H, Soe, Z, Moe, S · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 4 · 33.3%Very low 3 · 25%Low 1 · 8.3%Moderate 2 · 16.7%High 2 · 16.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aclidinium bromide compared to placebo for stable chronic obstructive pulmonary disease
Population: patients with stable chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (all‐cause) Aclidinium bromide vs placebo | OR 0.92 [0.43, 1.94] | 9 studies · 5252 participants | Low Downgraded: imprecision |
Exacerbations requiring steroids, antibiotics or both Aclidinium bromide vs placebo | OR 0.88 [0.74, 1.04] | 10 studies · 5624 participants | Moderate Downgraded: risk of bias, imprecision |
Quality of life Number of patients who achieved at least 4 units improvement in SGRQ total score Aclidinium bromide vs placebo | OR 1.49 [1.31, 1.7] | 7 studies · 4420 participants | High |
Functional capacity Six‐minute walking distance Aclidinium bromide vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Hospital admissions due to exacerbations Aclidinium bromide vs placebo | OR 0.64 [0.46, 0.88] | 10 studies · 5624 participants | High |
Non‐fatal serious adverse events Aclidinium bromide vs placebo | OR 0.89 [0.7, 1.14] | 10 studies · 5651 participants | Moderate Downgraded: risk of bias, imprecision |
Aclidinium bromide compared to tiotropium for stable chronic obstructive pulmonary disease
Population: patients with stable chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (all‐cause) Aclidinium bromide vs tiotropium | no estimate extracted | 1 study · 329 participants | Ungraded |
Exacerbations requiring steroids, antibiotics or both Aclidinium bromide vs tiotropium | OR 2.64 [0.31, 22.18] | 2 studies · 729 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life St George's Respiratory Questionnaire (SGRQ) score Aclidinium bromide vs tiotropium | no estimate extracted | 0 studies · 0 participants | Ungraded |
Functional capacity Six‐minute walk distance Aclidinium bromide vs tiotropium | no estimate extracted | 0 studies · 0 participants | Ungraded |
Hospital admissions due to exacerbations Aclidinium bromide vs tiotropium | OR 0.54 [0.07, 4.11] | 2 studies · 729 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal serious adverse events Aclidinium bromide vs tiotropium | OR 0.67 [0.17, 2.65] | 2 studies · 729 participants | Very low Downgraded: risk of bias, imprecision |